Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Nov 2021
Moderna booster progress ‘well advanced’ as regulator considers child vaccines
11 November 2021 - Moderna’s coronavirus vaccine could be approved for use as a booster within weeks and the medical ...
Posted by Michael Wonder on 11 Nov 2021
HSE approves reimbursement of Ajovy (fremanezumab) in migraine
11 November 2021 - Teva Pharmaceuticals Ireland has announced the approval of Ajovy (fremanezumab) 225 mg pre-filled syringe for prescription ...
Posted by Michael Wonder on 11 Nov 2021
Tremfya (guselkumab) approved for reimbursement in Ireland for active psoriatic arthritis
11 November 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that Tremfya (guselkumab), a first-in-class treatment ...
Posted by Michael Wonder on 11 Nov 2021
COVID-19 vaccine weekly safety report (11 November 2021)
11 November 2021 - To 7 November 2021, the TGA has received 288 reports which have been assessed as likely to ...
Posted by Michael Wonder on 10 Nov 2021
NICE terminates appraisal of new, first in class radioenhancer hafnium oxide nanoparticle
10 November 2021 - NBTXR3 is used to treat patients with sarcoma. ...
Posted by Michael Wonder on 10 Nov 2021
Ellume's COVID-19 home test recall most serious, FDA says
10 November 2021 - The U.S. FDA classified the recall of Ellume's over-the-counter COVID-19 home test as Class 1, the ...
Posted by Michael Wonder on 10 Nov 2021
Merck and Ridgeback announce Japanese Government to purchase 1.6 million courses of molnupiravir, an investigational oral COVID-19 anti-viral medicine, upon authorisation or approval
10 November 2021 - Merck and Ridgeback Biotherapeutics today announced that the Japanese government will purchase, upon authorization or approval, approximately ...
Posted by Michael Wonder on 10 Nov 2021
Why TGA head John Skerritt must go over vaccine claim
10 November 2021 - The head of the TGA must resign or be sacked over his claims about the Moderna vaccine. ...
Posted by Michael Wonder on 10 Nov 2021
The last drugstore: rural America is losing its pharmacies
10 November 2021 - Over 40 million rural Americans live in pharmacy deserts because of market consolidation. ...
Posted by Michael Wonder on 10 Nov 2021
KRPIA raises concern over HIRA’s cost effectiveness evaluation plan
10 November 2021 - Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over HIRA's plan of evaluating a drug’s cost ...
Posted by Michael Wonder on 10 Nov 2021
Roche executive says Alzheimer's drug price will be competitive
10 November 2021 - Roche, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking ...
Posted by Michael Wonder on 10 Nov 2021
SMC accepts oral therapy for relapsing multiple sclerosis
10 November 2021 - Janssen has announced that the SMC have accepted Ponvory (ponesimod) within NHS Scotland, as a treatment for ...
Posted by Michael Wonder on 10 Nov 2021
EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11
10 November 2021 - EMA has started evaluating an application to extend the use of Moderna’s COVID-19 vaccine, Spikevax, to ...
Posted by Michael Wonder on 10 Nov 2021
Universal health care is a fundamental right — being delusional is not
10 November 2021 - Singapore’s Health Ministry has announced that its citizens who choose not to be vaccinated will be ...
Posted by Michael Wonder on 10 Nov 2021
Health Canada authorises the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot
9 November 2021 - Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot. ...